Fidelity Investments
GRNA

Fidelity Investments’s GreenLight Biosciences Holdings, PBC Common Stock GRNA Stock Holding History

Fidelity Investments’s Portfolio GRNA Stock Details GRNA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q3 		– Sell
-6,358
Closed -$1.9K – 5655
2023
Q2 		$1.9K Sell
6,358
-2,867
-31% -$865 ﹤0.01% 4604
2023
Q1 		$3.99K Buy
9,225
+6,576
+248% +$5.05K ﹤0.01% 4450
2022
Q4 		$3.13K Buy
2,649
+2,292
+642% +$3.73K ﹤0.01% 4395
2022
Q3 		$1K Buy
+357
New +$935 ﹤0.01% 4780

Fidelity Investments's GRNA Position: Q3 2023 in Review

Fidelity Investments sold out of GreenLight Biosciences Holdings, PBC Common Stock (GRNA) in Q3 2023, closing a stake of 6,358 shares — an estimated $1.9K sold.

Fidelity Investments first reported a position in GRNA in Q3 2022 and held it in 4 quarters. The position peaked at $3.99K in Q1 2023. 0 funds tracked by Wall St. Rank hold GRNA as of Q3 2023.

  • Fidelity Investments reported no remaining GreenLight Biosciences Holdings, PBC Common Stock position as of Q3 2023 after selling out during the quarter.
  • Fidelity Investments sold 6,358 GreenLight Biosciences Holdings, PBC Common Stock shares in Q3 2023, an estimated $1.9K.
  • Fidelity Investments first reported a position in GreenLight Biosciences Holdings, PBC Common Stock in Q3 2022 and held it in 4 quarters.
  • Fidelity Investments's GreenLight Biosciences Holdings, PBC Common Stock position peaked at $3.99K in Q1 2023.
  • 0 funds tracked by Wall St. Rank held GreenLight Biosciences Holdings, PBC Common Stock as of Q3 2023.

Based on Fidelity Investments's 13F filing for Q3 2023, filed 13 Nov 2023.